Bevenopran
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | 676500-67-7 |
PubChem (CID) | 10452732 |
ChemSpider | 8628148 |
Chemical and physical data | |
Formula | C20H26N4O4 |
Molar mass | 386.44484 g/mol |
3D model (Jmol) | Interactive image |
| |
|
Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally selective μ- and δ-opioid receptor antagonist that was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation.[1][2][3] It reached phase III clinical trials for this indication before being discontinued.[4][5]
See also
References
- ↑ Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF (2011). "Novel opioid antagonists for opioid-induced bowel dysfunction". Expert Opin Investig Drugs. 20 (8): 1047–56. doi:10.1517/13543784.2011.592830. PMID 21663526.
- ↑ Siemens W, Gaertner J, Becker G (2015). "Advances in pharmacotherapy for opioid-induced constipation - a systematic review". Expert Opin Pharmacother. 16 (4): 515–32. doi:10.1517/14656566.2015.995625. PMID 25539282.
- ↑ Annual Reports in Medicinal Chemistry. Elsevier Science. 13 September 2013. pp. 451–. ISBN 978-0-12-417151-0.
- ↑ Combating Opioid-Induced Constipation: New and Emerging Therapies
- ↑ Bevenopran
This article is issued from Wikipedia - version of the 10/17/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.